Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi

Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

Pasadena. CA | Posted on June 27th, 2018

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on Arrowhead’s application for orphan designation of its RNAi candidate, ARO-AAT, for the treatment of congenital alpha-1 antitrypsin deficiency. ARO-AAT was previously granted orphan drug designation by the United States Food and Drug Administration in February 2018.

Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, said, “ARO-AAT has the potential to provide patients and physicians with a much-needed treatment option for liver disease associated with alpha-1 antitrypsin deficiency, a rare genetic disorder. The COMP’s adoption of a positive opinion for ARO-AAT orphan drug designation is another important milestone for this program, which continues to advance rapidly.”

The positive opinion issued by COMP will be sent to the European Commission which is expected to grant the orphan designation within 30 days. Orphan designation in the EU allows Arrowhead to benefit from a number of key incentives, including reduced regulatory fees, protocol assistance, and market exclusivity, to develop a medicine for the treatment of a rare disease affecting not more than five in 10,000 people in the European Union.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie, 212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Tracking pollen with quantum dots: A pollination biologist from Stellenbosch University in South Africa is using quantum dots to track the fate of individual pollen grains. This is breaking new ground in a field of research that has been hampered by the lack of a universal method February 17th, 2019

Super-light, super-insulating ceramic aerogel keeps the hottest temperatures at bay February 17th, 2019

Molecular Lego blocks: Chemical data mining boosts search for new organic semiconductors February 15th, 2019

The smallest skeletons in the marine world observed in 3D by synchrotron techniques February 15th, 2019

Govt.-Legislation/Regulation/Funding/Policy

NRL, AFRL develop direct-write quantum calligraphy in monolayer semiconductors February 15th, 2019

Researchers create ultra-lightweight ceramic material that withstands extreme temperatures: UCLA-led team develops highly durable aerogel that could ultimately be an upgrade for insulation on spacecraft February 15th, 2019

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Laser-induced graphene gets tough, with help: Rice University lab combines conductive foam with other materials for capable new composites February 12th, 2019

Nanomedicine

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Laser-induced graphene gets tough, with help: Rice University lab combines conductive foam with other materials for capable new composites February 12th, 2019

Nominations invited for $250,000 Kabiller Prize — the world’s largest monetary award for achievement in nanomedicine: An additional $10,000 award will honor a young investigator in nanoscience, nanomedicine February 7th, 2019

Kanazawa University research: Chirality inversion in a helical molecule at controlled speeds February 6th, 2019

Announcements

Tracking pollen with quantum dots: A pollination biologist from Stellenbosch University in South Africa is using quantum dots to track the fate of individual pollen grains. This is breaking new ground in a field of research that has been hampered by the lack of a universal method February 17th, 2019

Super-light, super-insulating ceramic aerogel keeps the hottest temperatures at bay February 17th, 2019

Researchers create ultra-lightweight ceramic material that withstands extreme temperatures: UCLA-led team develops highly durable aerogel that could ultimately be an upgrade for insulation on spacecraft February 15th, 2019

Spintronics by 'straintronics': Switching superferromagnetism with electric-field induced strain February 15th, 2019

Nanobiotechnology

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Nominations invited for $250,000 Kabiller Prize — the world’s largest monetary award for achievement in nanomedicine: An additional $10,000 award will honor a young investigator in nanoscience, nanomedicine February 7th, 2019

Kanazawa University research: Chirality inversion in a helical molecule at controlled speeds February 6th, 2019

Disruptive by Design: Nano Now February 1st, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project